IMB Dx, Inc. (KOSDAQ:461030)
South Korea · Delayed Price · Currency is KRW 5,280.00
-160.00 (-2.94%)
May 20, 2026, 3:30 PM KST
IMB Dx Company Description
IMBdx, Inc. engages in the development of liquid biopsy tests for cancer diagnosis.
It focuses on the following business areas: diagnosis and treatment of advanced cancer, early detection of recurrence after surgery, and early cancer diagnosis.
Its products include AlphaLiquid, CancerDetect, and CancerFind. The company was founded by Tae-Yu Kim, Sung-Tae Moon, and Doo-Hee Bang on July 5, 2018 and is headquartered in Seoul, South Korea.
IMB Dx, Inc.
| Country | South Korea |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Tae-You Kim |
Contact Details
Address: BYC Highcity Bldg A Seoul South Korea | |
| Phone | 82 2 6951 2906 |
Stock Details
| Ticker Symbol | 461030 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7461030009 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Tae-You Kim | Chief Executive Officer |
| Jin-Won Joo | Chief Financial Officer |